Pagh Anja, Grau Cai, Overgaard Jens
Department of Experimental Clinical Oncology, Aarhus University Hospital Denmark.
Acta Oncol. 2015 May;54(5):813-9. doi: 10.3109/0284186X.2015.1028591.
To test the hypothesis that head and neck cancer (HNC) patients are in need of specialized follow-up (FU). This was done by an evaluation of the FU activities in a cohort of patients followed longitudinally for five years with focus on optimal duration and interval of post-therapeutic follow-up.
The study evaluated a cohort consisting of 197 consecutive patients with HNC treated at Aarhus University Hospital from 1 January to 31 December 2009. The inclusion criteria was that patients should be deemed free of disease two months after completed primary curative intended treatment or after primary curative salvage. It left 141 patients available for analysis. Data were collected through a medical chart review and from the Danish Head and Neck Cancer Group (DAHANCA) database. Parameters recorded were: regular or extraordinary visit, alarm symptoms, late morbidity and the consequences of these.
The 141 patients underwent 1408 FU visits. Only 15 of the 141 patients had no tumor problems or morbidity issues raised at any FU visit. Suspicion of recurrent disease was observed at 207 of the 1408 FU visits, involving 97 patients and resulted in a total of 370 diagnostic procedures; 170 (82%) visits with suspicion of recurrence occurred within 3½ years after end of treatment. A recurrence was verified in 30 patients. Additionally four new primary head and neck cancer was diagnosed during follow-up. There were 1150 visits (82%) involving 135 patients in which late treatment-related morbidity was recorded. Actions taken related to morbidity happened in 71 patients, but no new problems appeared after three years.
The study document the need of specialized FU, as 86% of all HNC survivors have tumor or severe morbidity issues during FU. The data suggest that 3½-year FU after ended therapy may be sufficient for the majority of patients.
检验头颈癌(HNC)患者需要专门随访(FU)这一假设。通过评估一组纵向随访五年的患者的随访活动来进行检验,重点关注治疗后随访的最佳时长和间隔。
该研究评估了2009年1月1日至12月31日在奥胡斯大学医院接受治疗的197例连续HNC患者组成的队列。纳入标准是患者在完成初次根治性意向性治疗或初次根治性挽救治疗两个月后应被视为无疾病。最终有141例患者可供分析。数据通过病历审查和丹麦头颈癌组(DAHANCA)数据库收集。记录的参数包括:常规或特殊就诊、警示症状、晚期发病率及其后果。
141例患者接受了1408次随访就诊。141例患者中只有15例在任何随访就诊中均未出现肿瘤问题或发病问题。在1408次随访就诊中有207次观察到复发疾病疑似情况,涉及97例患者,共进行了370次诊断程序;82%(170次)复发疑似就诊发生在治疗结束后的3.5年内。30例患者复发得到证实。此外,随访期间诊断出4例新的原发性头颈癌。135例患者的1150次就诊(82%)记录了晚期治疗相关发病率。71例患者针对发病率采取了措施,但三年后未出现新问题。
该研究证明了专门随访的必要性,因为所有HNC幸存者中有86%在随访期间出现肿瘤或严重发病问题。数据表明,治疗结束后3.5年的随访可能对大多数患者足够。